Ex vivo drug sensitivity screening predicts response to temozolomide in glioblastoma patients and identifies candidate biomarkers.
Ioannis NtafoulisAnne KleijnJie JuKevin Jimenez-CowellFederica FabroMichelle KleinRomain Tching Chi YenRutger K BalversYunlei LiAndrew P StubbsTrisha V KersJohan M KrosSean E LawlerLaurens V BeerepootAndreas KremerAhmed IdbaihMaite VerreaultAnthony L ByrneAlice C O'FarrellKate ConnorArchita BiswasManuela SalvucciJochen H M PrehnDiether LambrechtsGonca DilcanFrancesca LodiIngrid ArijsMartin J Van Den BentClemens M F DirvenSieger Leenstranull nullMartine L M LamfersPublished in: British journal of cancer (2023)
GSCs retain patient-unique hallmark gene expressions despite loss of their natural environment. Drug screening using GSCs predicted patient response to TMZ more specifically than MGMT status, while transcriptome analysis identified potential biomarkers for this response. GSC drug screening therefore provides a tool to improve drug development and precision medicine for glioblastoma.